Colistin Pharmacokinetics in Burn Patients during Continuous Venovenous Hemofiltration

Kevin S. Akers,a,b Matthew P. Rowan,ab Krista L. Niece,a Ian J. Stewart,bb Katrin Mende,b,c Jason M. Cota,d Clinton K. Murray,ba Kevin K. Chungaa,b
United States Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas, USA; Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, USA; Infectious Diseases Clinical Research Program, Bethesda, Maryland, USA; University of the Incarnate Word, Feik School of Pharmacy, San Antonio, Texas, USA; Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

While colistin is considered a last resort for the treatment of multidrug-resistant Gram-negative bacterial infections, there has been an increase in its use due to the increasing prevalence of drug-resistant infections worldwide. The pharmacology of colistin is complex, and pharmacokinetic data are limited, especially in patients requiring renal replacement therapy. As a result, dosing for patients who require renal replacement remains a challenge. Here, we present pharmacokinetic data for colistin from two burn patients (37 and 68 years old) infected with colistin-susceptible isolocal Acinetobacter baumannii and receiving continuous venovenous hemofiltration (CVVH). To our knowledge, we are the first to examine data from before and during CVVH (for one patient), allowing analysis of the effect of CVVH on colistin pharmacokinetics. Pharmacokinetic/pharmacodynamic analysis indicated that a dose increase from 1.5 to 2.2 mg/kg of body weight colistin base activity on CVVH was insufficient to satisfy the target parameter of an AUC24/MIC (area under the concentration-time curve over 24 h in the steady state divided by the MIC) of ≥60 at an MIC of ≥1 µg/ml in one patient with residual endogenous renal function. Plasma concentrations of colistin ranged from 0 to 15 µg/ml, with free colistin levels ranging from 0.4 to 2.2 µg/ml. While both patients resolved their clinical infections and survived to discharge, colistin-resistant colonizing isolates resulted from therapy in one patient. The variabilities observed in colistin concentrations and pharmacokinetic characteristics highlight the importance of pharmacokinetic monitoring of antibiotics in patients undergoing renal replacement therapy.

An increase in the prevalence of multidrug-resistant Gram-negative infections worldwide (1, 2) and the lack of new antibiotics for the treatment of multidrug-resistant Gram-negative infections (3) have led to the increased use of polymyxin antibiotics (4), the most common of which are polymyxin B and polymyxin E (also known as colistin). Colistin is a multicomponent lipopeptide containing predominantly colistin A and colistin B, which differ only in the fatty acid chain attached to a cyclic decapptide moiety (5). To reduce toxicity (3), colistin is administered primarily as the prodrug colistin methanesulfonate (CMS), which is produced by sulfomethylation of five amino acid residues in colistin (6). Following parenteral administration, CMS undergoes hydrolysis in vivo to form a complex mixture of colistin and partially sulfomethylated derivatives (3). The rate of CMS conversion to formed colistin has not been well characterized in vivo but is thought to be lower than the rate of renal CMS elimination by unimpaired kidney function (6). In contrast, formed colistin undergoes predominantly nonrenal clearance through mechanisms yet to be elucidated (6).

Due to the complicated nature of CMS conversion to colistin in vivo, a lack of consensus on dosing guidelines (7, 8), and concerns about potential nephrotoxicity (6, 9), colistin has long been considered an agent of last resort for the treatment of Gram-negative infections. As the use of colistin predates modern preclinical testing requirements, pharmacokinetic data for colistin are limited. Given the increasing prevalence of multidrug-resistant Gram-negative infections and global use of colistin (2), more data are needed on the pharmacokinetics of colistin, particularly during continuous renal replacement therapies (CRRT), such as continuous venovenous hemofiltration (CVVH), which is being used more often to treat critically ill patients for its hemodynamic compatibility (10–13). Advances in high-performance liquid chromatography (HPLC) have allowed for the separation and identification of colistin in biological samples (5, 14–16). Here, we report plasma pharmacokinetic data for formed colistin in two burn patients treated for multidrug-resistant Acinetobacter baumannii infections undergoing CVVH, one of whom also underwent pharmacokinetic characterization prior to CVVH.

(A portion of this material was presented at ID Week 2013, Infectious Diseases Society of America, San Francisco, CA.)

CASE REPORT

Patient 1. A 68-year-old male with diabetes mellitus and hypertension was transferred to the burn intensive care unit (ICU) at the U.S. Army Institute of Surgical Research after suffering 2nd- and 3rd-degree burns to the chest, back, and upper extremities, totaling 11% of the total body surface area (TBSA), as well as moderate inhalational injury, from a house fire. He arrived me-

Address correspondence to Kevin S. Akers, kevin.s.akers.mil@mail.mil. Supplemental material for this article may be found at http://dx.doi.org/10.1128/AAC.03783-14.
Copyright © 2015, American Society for Microbiology. All Rights Reserved. doi:10.1128/AAC.03783-14
<table>
<thead>
<tr>
<th>1. REPORT DATE</th>
<th>2. REPORT TYPE</th>
<th>3. DATES COVERED</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 JAN 2015</td>
<td>N/A</td>
<td>-</td>
</tr>
</tbody>
</table>

4. TITLE AND SUBTITLE
Colistin Pharmacokinetics in Burn Patients During Continuous Venovenous Hemofiltration

6. AUTHOR(S)

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
United States Army Institute of Surgical Research, Fort Sam Houston, TX 78234

12. DISTRIBUTION/AVAILABILITY STATEMENT
Approved for public release, distribution unlimited

16. SECURITY CLASSIFICATION OF:
   a. REPORT  
      unclassified
   b. ABSTRACT  
      unclassified
   c. THIS PAGE  
      unclassified

   17. LIMITATION OF ABSTRACT  
       SAR
   18. NUMBER OF PAGES  
       7
   19a. NAME OF RESPONSIBLE PERSON


Standard Form 298 (Rev. 8-98)  
Prescribed by ANSI Std Z39-18
chemically ventilated and experienced two episodes of ventilator-associated pneumonia (VAP) during his hospital stay, diagnosed on hospital days (HD) 14 and 30, with serial recovery of *A. baumannii* from the respiratory tract. The initial isolate, recovered on hospital day 12, was tested for colistin susceptibility and demonstrated an MIC of 0.38 μg/ml by epiometer test (Etest) and resistance to all other antimicrobials tested. Additional isolates of *A. baumannii* were recovered from the respiratory tract up to hospital day 70 (see Fig. S1 in the supplemental material). Both episodes of VAP were treated with 14 days of intravenous (i.v.) CMS (Coly-Mycin M; Parkedale Pharmaceuticals, Rochester, MI) (4.4 mg colistin base activity [CBA]/kg of body weight/day in 2 divided doses) and nebulized CMS therapy (75 mg every 8 h). During the period of VAP treatment with colistin, he also received vancomycin titrated to renal function for skin graft donor site cellulitis and levofloxacin 750 mg i.v. for 3 days for empirical treatment of sepsis prior to the second episode of VAP (HD 26). During the second episode, empirical imipenem–cilastatin was added for Gram-negative rods recovered in bronchoalveolar lavage cultures, found to be multidrug/carbapenem-resistant *A. baumannii* and pan-susceptible *Klebsiella pneumoniae*. In addition to colistin, the patient received imipenem–cilastatin for 10 days.

On the day of pharmacokinetic sampling (HD 23, day 10 of the initial course of systemic and day 7 of nebulized CMS therapy), the patient received both i.v. CMS (2.2 mg CBA/kg every 12 h, infused over 30 min) and nebulized CMS (75 mg every 8 h). During sampling, the patient received CVVH (which was indicated for renal support) at a delivered dose of 38.1 ml/kg/h using a Prismaflex device (Gambro, Lakewood, CO) with an HF1400 polyarylether-sulfone filter. Replacement fluid (RFP401; NxStage) was infused prefilter only at 3 liters/h, with a polyethersulfone filter. Replacement fluid (RFP401; NxStage) was infused over 30 min at 2.9 mg CBA/kg/day (in 2 divided doses) after CVVH was prescribed at 35 ml/kg/h for therapy. During the period of VAP treatment with colistin, the patient received both i.v. CMS (2.2 mg CBA/kg every 12 h, infused over 30 min) and nebulized CMS therapy (75 mg every 8 h). During sampling, the patient received CVVH (which was indicated for renal support) at a delivered dose of 38.1 ml/kg/h using a Prismaflex device (Gambro, Lakewood, CO) with an HF1400 polyarylether-sulfone filter. Replacement fluid (RFP401; NxStage) was infused prefilter only at 3 liters/h, with a polyethersulfone filter. Replacement fluid (RFP401; NxStage) was infused over 30 min at 2.9 mg CBA/kg/day (in 2 divided doses) after CVVH was prescribed at 35 ml/kg/h for therapy.

During the first episode, empirical imipenem–cilastatin was added for Gram-negative rods recovered in bronchoalveolar lavage cultures, found to be multidrug/carbapenem-resistant *A. baumannii* and pan-susceptible *Klebsiella pneumoniae*. In addition to colistin, the patient received imipenem–cilastatin for 10 days.

Patient 2. A 37-year-old previously healthy male member of the U.S. military sustained 3rd-degree burns totaling 51% TBSA in a helicopter crash while overseas. After preliminary stabilization care at a combat support hospital, he underwent aeromedical evacuation to the United States and was admitted to the burn ICU at the U.S. Army Institute of Surgical Research 4 days after injury. Acute Kidney Injury Network stage 2 (17) and rhabdomyolysis were present upon admission. Orthopedic injuries included fractures of the humerus and patella. Blood cultures drawn upon admission, and subsequently bronchoalveolar lavage fluid, contained *A. baumannii*, susceptible only to colistin with an MIC of 0.75 μg/ml, as determined by Etest. Additional isolates were recovered from superficial cultures of intact and debrided skin from various body sites (see Fig. S1 in the supplemental material).

CMS was infused over 30 min at 2.9 mg CBA/kg/day (in 2 divided doses) initially and increased to 4.4 mg CBA/kg/day (2 divided doses) after CVVH was prescribed at 35 ml/kg/h for therapy of acute kidney injury (AKI) with metabolic acidosis. CMS was also given by nebulizer three times daily (75 mg every 8 h). During colistin therapy, the patient also received empirical treatment with vancomycin titrated to renal function and imipenem–cilastatin 250 to 500 mg every 6 h, although the recovered *A. baumannii* isolates were resistant to imipenem. In addition, doxycycline 100 mg daily was given for terminal malaria prophylaxis. During pharmacokinetic sampling, the patient received CVVH at a delivered dose of 28.4 ± 3.7 ml/kg/h using an NxStage device (NxStage Medical, Lawrence, MA) with a CAR500 polyethersulfone filter. Replacement fluid (RFP401; NxStage) was infused prefilter only at 3 liters/h, with a Qf of 250 ml/min and an ultrafiltration rate of 300 ml/h. The 24-h urine output on the day of sampling was 2,263 ml (0.9 ml/kg/h). Patient 2 survived to hospital discharge 154 days after admission with no clinical evidence of recurrent VAP. However, additional colonizing isolates of *A. baumannii* were recovered, including a colistin-resistant isolate (MIC, 24 μg/ml) from the respiratory tract (HD 47) which appeared to revert to being colistin susceptible (MIC, 1 μg/ml, on HD 52). An isolate with high-level colistin resistance (MIC, >256 g/ml) was recovered on a rectal surveillance swab on HD 101. Both colistin-resistant isolates remained resistant to all other first-line antimicrobials, and all isolates shared the identical pulsed-field gel electrophoresis (PFGE) pattern (see Fig. S1 in the supplemental material).

**MATERIALS AND METHODS**

**Materials.** All drugs and chemicals were reagent grade and were obtained from Sigma (St. Louis, MO) unless otherwise noted.

**Pharmacokinetic sampling and analysis.** Pharmacokinetic sampling of single dose curves was performed following the surrogate’s informed consent as part of an ongoing prospective observational pharmacokinetic (PK) and pharmacodynamic (PD) study in trauma and burn patients approved by the U.S. Army Medical Research and Materiel Command Institutional Review Board. Three milliliters of whole blood was sampled at 0 (predose), 1, 2, 4, 8, and 12 h from the start of infusion. The samples obtained during CVVH therapy included prefilter blood and ultrafiltrate specimens. Plasma was separated from whole blood by centrifugation at 2,000 × g for 10 min at 4°C, and the plasma or ultrafiltrate sample was immediately frozen at −80°C until analysis. Pharmacokinetic parameters were estimated by noncompartmental analysis using WinNonLin software, version 6.3 (Pharsight, Cary, NC). The total (bound plus free) colistin AUC24/MIC (area under the concentration-time curve over 24 h in the steady state divided by the MIC) of ≥60, derived from a large population pharmacokinetic analysis (18), was selected as the target value to determine adequacy of therapy. When calculating the sieving coefficient (S), prefilter blood concentrations were multiplied by the following factor to correct for the dilution effects of prefilter replacement fluids: Qf/(Qf + Qrep), representing prefilter flow rates of blood (Qf) and replacement fluid (Qrep). The S was calculated as the ratio of the area under the curve (AUC) for the time-concentration curve for the ultrafiltrate to the dilution-corrected AUC of plasma (19, 20).

**Sample preparation.** Colistin derivatization and isolation from plasma were performed as described previously (15–19). Briefly, 200 μl plasma was spiked with netilmicin (100 ng, internal standard) and loaded under vacuum onto a solid-phase extraction column (Sep-Pak C18; Waters, Milford, MA) previously conditioned with methanol (1 ml) and 1% sodium bicarbonate (1 ml, pH 10). After washing with sodium bicarbonate (500 μl), 30 μl of freshly prepared 9-fluorenethyl chloroformate (FMOC-Cl) was added and drawn into the extraction column. The derivatization reaction was allowed to proceed for 10 min before drying the column under vacuum. Reaction products were eluted with acetone (900 μl) and mixed with sodium borate (0.2 M, 600 μl, pH 8.5). A total of 20 μl of each sample was assayed by HPLC. Calibration curves were prepared by creating solutions of blank human plasma containing 0.1 to 10 μg/ml CBA, which were processed in parallel to the samples. Free (unbound) colistin was determined by filter centrifugation (Centriprep ultrafiltrate [UF], 30 kDa; Millipore, Billerica, MA) of plasma at 1,500 × g for 30 min. Despite reports of extensive nonspecific binding to membranes of similar
TABLE 1 Patient characteristics and pharmacokinetic data for colistin in plasma samples from patients undergoing CVVH

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patient 1</th>
<th>Patient 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)/gender</td>
<td>68/male</td>
<td>37/male</td>
</tr>
<tr>
<td>% TBSA burn</td>
<td>11</td>
<td>51</td>
</tr>
<tr>
<td>CVVH delivered dose (mean ± SD) (ml/kg)</td>
<td>38.1 ± 11.0</td>
<td>28.0 ± 3.7</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>136.4</td>
<td>86.6</td>
</tr>
<tr>
<td>Urine output (ml/kg/h)</td>
<td>0.2</td>
<td>1.6</td>
</tr>
<tr>
<td>Machine and filter</td>
<td>Prismaflex, HF1400</td>
<td>NxStage, CAR500</td>
</tr>
<tr>
<td>Prefilter fluid replacement (liters/h)</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Colistin CMS dose (mg/kg)</td>
<td>2.2</td>
<td>1.5</td>
</tr>
<tr>
<td>Colistin % TBSA burn</td>
<td>11</td>
<td>51</td>
</tr>
<tr>
<td>Colistin AUC24 (µg·h/ml)</td>
<td>222.2 (18.2 free)</td>
<td>22.4 (1.4 free)</td>
</tr>
<tr>
<td>Colistin V (liters)</td>
<td>86.1</td>
<td>99.7</td>
</tr>
<tr>
<td>Colistin Clearance (liters/h)</td>
<td>2.7</td>
<td>4.7</td>
</tr>
<tr>
<td>% CVVH clearance</td>
<td>51.6</td>
<td>0.04</td>
</tr>
<tr>
<td>Sieving coefficient</td>
<td>0.49</td>
<td>0.17</td>
</tr>
<tr>
<td>% Free colistin (mean ± SD)</td>
<td>11.9 ± 9.2</td>
<td>13.7 ± 6.4</td>
</tr>
<tr>
<td>% Colistin A (mean ± SD)</td>
<td>64.8 ± 1.4</td>
<td>67.7 ± 0.4</td>
</tr>
<tr>
<td>% Colistin B (mean ± SD)</td>
<td>14.1 ± 1.7</td>
<td>10.9 ± 4.6</td>
</tr>
<tr>
<td>MIC at which AUC24/MIC was ≥60 (µg/ml)</td>
<td>2</td>
<td>0.75</td>
</tr>
</tbody>
</table>

a Colistin peak area of colistin A and B and dividing by the peak area of the internal standard.

b Only 0- to 8-h data available due to filter clotting.

destained with water, imaged with the U:Genius system (Syngene, Frederick, MD), and analyzed with BioNumerics software (Applied Maths, Austin, TX). The PFGE patterns were interpreted and grouped into pulsed-field types using established criteria (25).

RESULTS
Pharmacokinetic parameters of colistin (Table 1) were estimated using noncompartmental analysis from the time-concentration curves for colistin (Fig. 1). In the plasma samples, the proportions of colistin A and B were approximately 65 to 68% and 10 to 14%, respectively, before and during CVVH. Interestingly, colistin B was cleared across the filter membrane slightly more readily than colistin A (difference from plasma, −14.2% for A versus +16.5% for B). AUC24/MIC curves were calculated for hypothetical MICs, indicating that the increased clearance associated with CVVH has the potential to compromise PK/PD targets, particularly with higher MICs and preserved renal function (Fig. 2). A PFGE analysis of A. baumannii isolates indicated that the same strain was present in all sample locations throughout the hospital stay for each patient (Dice coefficient, ≥95%; see Fig. S1 in the supplemental material). Colistin MICs ranged from 0.75 to 1.0 µg/ml for patient 1. MICs for susceptible isolates from patient 2 ranged from 0.5 to 1.5 µg/ml, with two colistin-resistant colonizing isolates having MICs from 24 to >256 µg/ml.

DISCUSSION
Colistin, approved for parenteral use in the United States as the prodrug colistin methanesulfonate, has seen a resurgence of use in the last decade as a drug of last resort for multidrug-resistant Gram-negative organisms. As it was developed prior to modern regulatory requirements, which include rigorous pharmacoki-
macokinetic study, significant uncertainties persist regarding its disposition in humans. Methods for the analysis of colistin by HPLC have been described (14–16, 22, 23), resulting in an increase in pharmacokinetic studies in patients. The most comprehensive pharmacokinetic study to date included 851 sample observations from 105 subjects (18), of which 12 were treated with hemodialysis and 4 were treated with CRRT; of these, 3 were treated with continuous venovenous hemodiafiltration (CVVHDF) and 1 received CVVH. Since CVVHDF uses passive diffusion across a concentration gradient in addition to hemodiafiltration (the sole method for CVVH), the equivalences of these modes with respect to CMS/colistin clearance are unknown. Additionally, recent reports have described CMS and colistin pharmacokinetics in patients undergoing CVVHDF (26) and dialysis (27), but to our knowledge, this is the first study to report on the pharmacokinetics of colistin in the same individual prior to and during CVVH therapy. Evaluation of the pharmacokinetic data for colistin before and during CVVH affords the opportunity to directly study the impact of CVVH on colistin pharmacokinetics.

After administration, colistin is a complex mixture of at least 30 hydrolysis products of the prodrug CMS, with colistin A and B serving as the major products (6, 14). The pharmacokinetic dispositions of CMS and colistin in humans are equally complex, especially under conditions of CVVH therapy, with CMS being cleared renally but colistin being cleared by poorly defined non-renal mechanisms. Additionally, the in vivo rate and extent of conversion from CMS to colistin are unknown but are thought to be lower than the renal clearance of CMS by unimpaired kidneys (6), and there is uncertainty as to whether CMS hydrolysis is spontaneous or enzymatically catalyzed (3, 6). Despite the fact that the CVVH circuit and apparatus can functionally increase the volume of distribution (V), the V of patient 1 (during CVVH) was slightly lower than that of patient 2 (without CVVH). This may reflect a reduced circulating plasma volume due to fluid losses from ultrafiltration. CRRT further complicates the situation, as data describing the rate of CRRT clearance of CMS and colistin or to what extent CRRT clearance of CMS may be offset by a reduced glomerular filtration rate are sparse. Other than monitoring of urine output, there are no methods currently available to determine the degree of intrinsic renal function while receiving CRRT. Additionally, there are various modes of CRRT utilized with various doses that are prescribed. The use of intermittent modes of renal replacement in many units with hybrid techniques, such as sustained low-efficiency dialysis, also complicates the picture (28–30). As a result, CMS dosing for patients who require renal replacement remains a challenge.

While this study provides valuable in vivo pharmacokinetic data for colistin in patients undergoing CVVH and, for the first time, pharmacokinetic data for colistin before and during CVVH, some limitations of this study require caution in drawing broad conclusions. The small sample size (two patients) and lack of data for CMS limit the statistical comparisons and reduce the power of analyses. Unfortunately, filter clotting in patient 2 during CVVH, which may have caused a rise in the plasma colistin concentration prior to clotting, prevented calculation of the full suite of PK parameters, because a terminal clearance slope was not determined. Further, although samples were kept cold during the analytical procedures, some spontaneous conversion of CMS to colistin in ultrafiltrate and plasma samples during or after collection is possible (14), particularly in the ultrafiltrate that is sampled from fluid collected at ambient temperature over a long sampling interval. However, concentrations of formed colistin in the ultrafiltrate were similar at the beginning and end of sampling. Additionally, the patients were treated with nebulized CMS during CVVH and pharmacokinetic sampling, which may complicate the interpretation of colistin plasma concentrations, but inhaled colistin has been shown to have minimal systemic absorption at doses higher than those observed here (31, 32). Due to the inherent limitations in the system of care at the U.S. Army Institute of Surgical Re-
search, we were not able to ascertain the age of the CVVH filters at the time of sampling. This is relevant because the sieving efficiency of individual filters is known to degrade over time (33), likely as a result of proteinaceous fouling (34). Thus, newly placed filters in the CVVH circuit may have enhanced solute clearance relative to older filters. While the delivered CVVH doses during colistin PK sampling reflect those typically used for renal support (10–13), higher doses have been used for sepsis and other states of shock (13, 35, 36). The impact of higher CVVH doses on colistin and other antimicrobials remains to be determined.

A previous analysis, based upon population pharmacokinetics derived from three nonburned CVVHD patients and one CVVH patient, has suggested that a daily dose of 192 mg CBA (irrespective of body weight) is necessary for each 1.0-μg/ml steady-state average colistin concentration \( \left( C_{ss,avg} \right) \) during continuous renal replacement (18). In our study, patient 1 received 600 mg daily during CVVH, but this resulted in a plasma \( C_{ss,avg} \) above the predicted value (predicted \( C_{ss,avg} \) 3.1 μg/ml; measured \( C_{ss,avg} \) 9.3 μg/ml). In contrast, the \( C_{ss,avg} \) for patient 2, who received 450 mg daily during CVVH, was accurately predicted (predicted \( C_{ss,avg} \) 2.3 μg/ml; measured \( C_{ss,avg} \) 2.3 μg/ml). This difference may be attributable to the greater preservation of endogenous renal function in patient 2, as reflected by urinary output. In addition, potential drug interactions impairing the clearance of colistin are impossible to assess, given that the mechanism for colistin clearance (which is nonrenal) remains unknown.

Colistin has been reported to have 59 to 74% protein binding (26 to 41% unbound fraction) in a study of nonburned critically ill patients (37), whereas we observed slightly higher protein binding of 80 to 90%. The increased protein binding we observed relative to previous reports may be due to prolonged elevation in alpha-1-acid glycoprotein, as occurs in burn patients (38, 39) and to which colistin has moderate binding affinity (40). This highlights the need for further detailed studies examining free colistin pharmacokinetics in burn patients, as a previous population pharmacokinetic model derived from burn patients did not incorporate protein binding data (41) and the unbound fraction has been identified as a relevant PK/PD parameter (42). The values before and during CVVH were similar for patient 2 (Table 1), suggesting that CVVH did not affect the protein binding status of colistin. This highlights the uncertain and variable results of CMS dosing and suggests a need for therapeutic drug monitoring to achieve optimal levels during CVVH, particularly for oliguric or anuric patients.

Colistin MIC values before and during therapy were below the CLSI "susceptible" breakpoint of 2 μg/ml. It is notable, therefore, that for patient 2, an increase in the CMS dose from 2.9 to 4.4 mg CBA/kg/day (2 divided doses) during CVVH was insufficient to achieve an AUC\(_{24}/M\text{IC} \geq 60\) when the MIC was \( \geq 1 \mu g/ml \) (Fig. 2). Thus, isolates determined to be susceptible according to current CLSI interpretive criteria may receive inadequate therapy despite achieving the predicted plasma concentration. Indeed, Ga-ronzık et al. (18) were prudent to acknowledge that their recommended maintenance doses may not be reliably effective against isolates with colistin MICs of >0.5 μg/ml. Published reports of treatment-associated colistin resistance are accumulating in the literature (43–45), perhaps corroborating in vitro data suggesting that no regimen of colistin monotherapy (including continuous infusion) can prevent colistin resistance in A. baumannii (46). Additionally, colistin resistance arose in patient 2 despite concurrent therapy with vancomycin and imipenem, which in vitro data suggest may be able to prevent the emergence of resistance when given concurrently with colistin (46).

Despite its limitations, this study provides an opportunity to examine the total clearance and fractional CVVH-related clearance rates for colistin and adds to the existing pharmacokinetic data for an increasingly common antibiotic for increasingly common multidrug-resistant bacterial infections. We observed significant variability in colistin concentrations resulting from recommended dosing strategies, with high and low concentration excursions in the setting of CVVH, suggesting risks for toxicity and compromised PK/PD target attainment, respectively. In our opinion, this study highlights the importance of antibiotic PK/PD monitoring in intensive care unit (ICU) patients, particularly those undergoing continuous renal replacement therapy.

**ACKNOWLEDGMENTS**

This study was conducted under a protocol reviewed and approved by the U.S. Army Medical Research and Materiel Command Institutional Review Board in accordance with approved protocol H-09-059. This work was supported by Defense Medical Research & Development Program (DMRPD) Military Infectious Disease Clinical Trial Award (Mid-CTA) D_MIDCTA_1_12_J2_299 and, in part, by an appointment to the Postgraduate Research Participation Program at the U.S. Army Institute of Surgical Research administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and USAMRMC.

We gratefully acknowledge the invaluable contributions of Doug Johnson, Kristie Harnisch, Crystal Rosemann, Lance Ferguson, and the participating research subjects, without whom this research would not be possible.

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.

**REFERENCES**


